TY - JOUR
T1 - Plasma from poorly mobilizing human subjects inhibits cytokine-induced murine blood stem-cell mobilization
AU - Sharp, Jg
AU - McGuire, Tr
AU - Mann, Sl
AU - Murphy, B.
AU - Kessinger, A.
N1 - Funding Information:
This research was supported by the US Army Medical Materiel Command, but no endorsement is implied, and by the Nebraska Research Initiative.
PY - 2002
Y1 - 2002
N2 - Background: Cytokine-induced mobilization of hematopoietic stem/progenitor cells to the circulation facilitates efficient harvest of blood stem cells by leukapheresis. Up to 30% of autologous, and 10-20% of allogeneic blood stem-cell donors respond poorly to mobilizing cytokines and preliminary studies implicated a circulating inhibitor of mobilization. Methods: In this study, plasma from 11 allogeneic and 23 autologous stem cell donors was assayed for inhibition of mobilization in mice. Results: There were significant correlations between CD34+ cells collected/kg human donor weight and spleen weight, CD34+ CD45+ cells, GM-CFC and HPP-CFC per spleen in murine recipients of these plasma samples. Overall, there was a positive association between transforming growth factor β (TGF-β) levels and CD34+ cells per liter of blood processed (LBP). However, when arbitrarily segregated into good versus poor mobilizer, based on less or greater than 15 million CD34+ cells collected per LBP, the majority (64%) of normal donors were good mobilizers. The majority of the poor mobilizers (83%) were patients. For a subset of 12 individuals whose plasma strongly inhibited mobilization in the mouse, a significant positive correlation of the extent of inhibition with TGF-β levels was found. For 11 individuals whose plasma, based on colony assays, enhanced mobilization when injected into mice, no correlation with TGF-β levels was evident. Discussion: Elevated plasma TGF-β levels in some stem-cell donors may be associated with poor stem-cell mobilization. It remains to be determined whether elevation of TGF-β levels is a cause of, or a compensatory response to, poor mobilization.
AB - Background: Cytokine-induced mobilization of hematopoietic stem/progenitor cells to the circulation facilitates efficient harvest of blood stem cells by leukapheresis. Up to 30% of autologous, and 10-20% of allogeneic blood stem-cell donors respond poorly to mobilizing cytokines and preliminary studies implicated a circulating inhibitor of mobilization. Methods: In this study, plasma from 11 allogeneic and 23 autologous stem cell donors was assayed for inhibition of mobilization in mice. Results: There were significant correlations between CD34+ cells collected/kg human donor weight and spleen weight, CD34+ CD45+ cells, GM-CFC and HPP-CFC per spleen in murine recipients of these plasma samples. Overall, there was a positive association between transforming growth factor β (TGF-β) levels and CD34+ cells per liter of blood processed (LBP). However, when arbitrarily segregated into good versus poor mobilizer, based on less or greater than 15 million CD34+ cells collected per LBP, the majority (64%) of normal donors were good mobilizers. The majority of the poor mobilizers (83%) were patients. For a subset of 12 individuals whose plasma strongly inhibited mobilization in the mouse, a significant positive correlation of the extent of inhibition with TGF-β levels was found. For 11 individuals whose plasma, based on colony assays, enhanced mobilization when injected into mice, no correlation with TGF-β levels was evident. Discussion: Elevated plasma TGF-β levels in some stem-cell donors may be associated with poor stem-cell mobilization. It remains to be determined whether elevation of TGF-β levels is a cause of, or a compensatory response to, poor mobilization.
KW - Inhibition of (stem cell) mobilization
KW - TGF-β
UR - http://www.scopus.com/inward/record.url?scp=0036383423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036383423&partnerID=8YFLogxK
U2 - 10.1080/146532402760271154
DO - 10.1080/146532402760271154
M3 - Article
C2 - 12396837
AN - SCOPUS:0036383423
SN - 1465-3249
VL - 4
SP - 365
EP - 373
JO - Cytotherapy
JF - Cytotherapy
IS - 4
ER -